Advertisement

Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy

  • Wafaa S. El-Sherbeny
  • Nesreen M. Sabry
  • Radwa M. Sharbay
Original Investigation
  • 99 Downloads

Abstract

Background

Adjuvant trastuzumab improved overall survival and reduced the risk for disease recurrence in women with breast cancers, because of its potential cardiotoxicity, careful monitoring of left ventricular (LV) function during treatment is required.

Methods

This study investigates, whether myocardial strain imaging and level of N-terminal pro-brain natriuretic peptide (NT-pro BNP) could predict subsequent reduction in LVEF in breast cancer patients received adjuvant trastuzumab. 61 women with pathologically proven breast cancer HER-2 positive received AC (Doxorubicin–Cyclophosphamide) for 4 cycles, followed by paclitaxel with Trastuzumab were enrolled. Clinical, conventional echocardiographic parameters, myocardial strain imaging [global longitudinal peak systolic strain (GLS), radial and circumferential systolic strain] and level of NT pro-BNP were measured at baseline, after 3, 6, 9 and 12 months of trastuzumab therapy.

Results

Of 61 patients, 18 patients (29.5%) developed trastuzumab-induced cardiomyopathy (CM) at 6 and 9 months of therapy (LVEF declines ≥ 10%), GLS and radial strain significantly decreased in CM group at 3 months of trastuzumab treatment, the value of GLS at 3 months was the strongest predictors of cardiotoxicity its area under the curve (AUC 0.98) with an optimal cut-off for GLS (− 18%) having 92.5% sensitivity and 83% specificity. NT-pro BNP levels were not predictive of later trastuzumab-induced cardiac dysfunction.

Conclusion

Myocardial strain imaging has been able to predict pre-clinical changes in LV systolic function and GLS is an independent early predictor of subsequent reduction in EF in breast cancer patients treated with trastuzumab.

Keywords

Breast cancer Trastuzumab Cardiotoxicity Myocardial strain 

Notes

Funding

This study was not funded.

Compliance with ethical standards

Conflict of interest

Wafaa S. El-Sherbeny, Nesreen M. Sabry and Radwa M. Sharbay declare that they have no conflict of interest.

Ethical approval

This study was approved by the Ethics Committee in the Faculty of Medicine, Tanta University and with Helsinki Declaration of 1964 and later revision.

Informed consent

Informed consent was obtained from all patients included in the study.

References

  1. 1.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, et al. Cancer statistics 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMedGoogle Scholar
  3. 3.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.CrossRefPubMedGoogle Scholar
  5. 5.
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Mackey JR, Clemons M, Cote MA, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008;15:24–35.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Otterstad JE, Froeland G, St. John Sutton M, et al. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J. 1997;18:507–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2008;26:1201–3.CrossRefPubMedGoogle Scholar
  10. 10.
    Eidem BW. Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough. J Am Soc Echocardiogr. 2008;21:1290–2.CrossRefPubMedGoogle Scholar
  11. 11.
    Mondillo S, Galderisi M, Mele D, et al. Speckle-tracking echocardiography: a new technique for assessing myocardial function. J Ultrasound Med. 2011;30:71–83.CrossRefPubMedGoogle Scholar
  12. 12.
    Goel S, Simes RJ, Beith JM. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia Pac J Clin Oncol. 2011;7(3):276–80.CrossRefPubMedGoogle Scholar
  13. 13.
    Teske AJ, De Boeek BW, Melman PG, et al. Echocardiographic quantification of myocardial function using tissue deformation imaging, a guide to image accession and analysis using tissue Doppler and speckle tracking. Ultrasound. 2007;5:27.Google Scholar
  14. 14.
    Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011;108:619–28.CrossRefPubMedGoogle Scholar
  16. 16.
    Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Procter M, Suter TM, de Azambuja E, et al. Long-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Piotrowski G, Gawor R, Bourge RC, et al. Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: a prospective study. Pharmacol Res. 2013;78:41–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Naumann D, Rusius V, Margiotta C, et al. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2 ± breast cancer. Anticancer Res. 2013;33(4):1717–20.PubMedGoogle Scholar
  21. 21.
    Romond EH, Jeong JH, Rastogi P, et al. Seven-year segment assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Xue J, Jiang Z, Qi F, et al. Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study. J Breast Cancer. 2014;17(4):363–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Piotrowski G, Gawor R, Bourge RC, et al. Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: a prospective study. Pharmacol Res. 2013;78:41–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63(8):809–16.CrossRefPubMedGoogle Scholar
  26. 26.
    Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Grover S, Leong DP, Chakrabarty A, et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol. 2013;168(6):5465–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Hare JL, Brown JK, Leano R, et al. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J. 2009;158:294–301.CrossRefPubMedGoogle Scholar
  29. 29.
    Ho E, Brown A, Barrett P, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the longterm follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart. 2010;96:701–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375–80.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011;57(22):2263–70.CrossRefPubMedGoogle Scholar
  32. 32.
    Negishi K, Negishi T, Hare JL, et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26:493–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Serrano C, Cortes J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2012;23:897–902.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Echocardiography 2018

Authors and Affiliations

  • Wafaa S. El-Sherbeny
    • 1
  • Nesreen M. Sabry
    • 2
  • Radwa M. Sharbay
    • 3
  1. 1.Cardiovascular Medicine Department, Faculty of MedicineTanta UniversityTantaEgypt
  2. 2.Clinical Oncology Department, Faculty of MedicineTanta UniversityTantaEgypt
  3. 3.Clinical Pathology Department, Faculty of MedicineTanta UniversityTantaEgypt

Personalised recommendations